Bradway Robert A 4

What Happened

• Robert A. Bradway, Amgen's Chairman, CEO and President, received equity awards on 2026-05-05: 12,136 restricted stock units (RSUs) and 79,176 derivative awards (non-qualified stock options) associated with a grant price/reference of $329.59. The derivative portion is reported with a total value of $26,095,618. On 2026-05-06, 1,702 shares were surrendered/withheld to satisfy tax withholding obligations, valued at $329.59 per share (total ≈ $560,962).

Key Details

• Transaction dates: awards granted 2026-05-05; tax withholding 2026-05-06; Form 4 filed 2026-05-07 (timely).
• Award amounts: 12,136 RSUs (acquisition price $0 reported) and 79,176 derivative awards (reported value $26,095,618).
• Tax withholding: 1,702 shares disposed at $329.59/share for ~$560,962 (code F — payment of exercise price or tax liability).
• Footnotes: RSUs vest in four equal annual installments beginning 5/5/2027 (F1); RSUs include 1,520 Dividend Equivalents credited to unvested RSUs (F2); the derivative awards are non‑qualified stock options vesting in four equal annual installments beginning 5/5/2027 (F3).
• Shares owned after the transaction: not specified in the provided filing.

Context

• These were grant-type awards (A) rather than open-market purchases or sales; the withheld shares were used to meet tax obligations (common practice), not an open-market sale signaling intent. The options and RSUs vest over four years starting 5/5/2027, so economic benefit is tied to future vesting.